Institute for Neurodegenerative Disorders
50
2
2
36
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
22.0%
11 terminated/withdrawn out of 50 trials
76.6%
-9.9% vs industry average
2%
1 trials in Phase 3/4
6%
2 of 36 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (50)
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Role: collaborator
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
Role: collaborator
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
Role: collaborator
PPMI Tau PET Imaging
Role: collaborator
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
Role: lead
A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease
Role: lead
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
Role: lead
Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects
Role: lead
Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
Role: lead
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Role: lead
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
Role: lead
Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects
Role: lead
The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
Role: lead
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
Role: lead
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
Role: lead
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
Role: lead
A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
Role: lead
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Role: lead
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
Role: lead
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Role: collaborator